Key result
A 49-year-old man with COVID-19-induced myocarditis and decompensated heart failure was successfully treated with intravenous dexamethasone, leading to clinical recovery and discharge.
Why the study?
The prevalence of COVID myocarditis is unclear but generally considered rare, though affected patients often suffer catastrophic worsening disease and death.
Case Report (n=1)
No
Dexamethasone may be a successful treatment option for patients with COVID-19-induced myocarditis.
Answers are grounded in this paper and cite their sources.
COVID myocarditis prevalence data remain too limited for routine screening; leaves open need for prospective incidence and outcome studies.
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), emerged in Wuhan, China, and rapidly led to a global pandemic that affected 213 countries, more than 5.8 million cases, and 360,000 deaths worldwide as of May 28, 2020. The United States currently has the highest number of COVID-19 cases in the world and contributes to nearly a third of the global death rate. The prevalence of COVID myocarditis is unclear but generally considered rare, with estimates up to 7% of COVID-related deaths. However, these patients suffered catastrophic worsening disease with respiratory compromise requiring intubation and often death. We report the case of a patient with COVID-19-induced myocarditis who was successfully treated with dexamethasone and review the literature.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2021) conducted a case report in COVID-19 Myocarditis (n=1). Dexamethasone was evaluated on Clinical recovery. A 49-year-old man with COVID-19-induced myocarditis and decompensated heart failure was successfully treated with intravenous dexamethasone, leading to clinical recovery and discharge.
Synapse has enriched 10 related papers. Consider them for comparative context: